From artificial intelligence-based drug discovery to cell and gene therapy, to precision genome editing and other newer technologies, biotechnology is in the midst of numerous research and clinical advances. Those advances are fueling recoveries for the markets that generate capital for the industry, from the venture capital that powers private startups, to the initial public offerings (IPO) of companies further along in development.

In The State of Biotech 2024—sponsored exclusively by Cytiva—GEN proudly brings together notables from industry and academia to discuss the latest research developments, innovations and disruptive technologies that will spur biotech forward to bigger and better things.

• A keynote presentation by Sonia Vallabh, PhD, co-leader of the Broad Institute’s initiative to develop preventive drugs for prion disease.
• A keynote address by David Altshuler, MD, PhD, Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals.
• Another keynote address from John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO).
• Panel discussions on biotech business trends with the co-hosts of the popular weekly Biotech Hangout podcast, and on the state of artificial intelligence with industry experts. 
• Leaders of an exciting collaboration focused on developing CRISPR-based therapies, involving Danaher and the Innovative Genomics Institute (IGI).
• A conversation with Tim Harris, author of “In Pursuit of Unicorns: A Journey through 50 Years of Biotechnology,” a memoir chronicling the industry’s birth and maturation.
• Breakout sessions and more.

The State of Biotech is  GEN’s flagship virtual event, following its successful introduction in 2022 and expansion last year. Registration is entirely free.